Author

S. Chopra

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Organism:bacteria (other)· 1 Assay:bulk RNA-seq· 1 Organism:human· 1 Assay:metagenomics· 1

Frequent Co-Authors

S. Singh· 2 shared A. Akhir· 1 shared A. Dasgupta· 1 shared A. Emmanuelli· 1 shared A. Foye· 1 shared A. Singh· 1 shared B. A. Cho· 1 shared C. Salvagno· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

S. Singh

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

An Arm-to-Disarm Strategy to Overcome Phenotypic AMR in Mycobacterium tuberculosis

T. A. Kumar, S. Birua, S. C. M, P. Mukherjee, S. Singh, G. Kaul, A. Akhir, S. Chopra, J. Hirschi, A. Singh, H. Chakrapani

This paper develops a prodrug strategy to overcome phenotypic AMR in Mtb by enhancing drug permeability and targeting hypoxic persisters.

bioRxiv · Mar 23, 2023Microbiology

Inflammatory ER Stress Responses Dictate the Immunopathogenic Progression of Systemic Candidiasis

D. Awasthi, S. Chopra, B. A. Cho, A. Emmanuelli, T. A. Sandoval, S.-M. Hwang, C.-S. Chae, C. Salvagno, C. Tan, L. Vasquez-Urbina, J. J. Fernandez Rodriguez, S. F. Santagostino, T. R. Iwawaki, E. A. Romero-Sandoval, M. Sanchez Crespo, , J. R. Cubillos-Ruiz

This study shows that IRE1 hyperactivation in myeloid cells during Candida albicans infection drives renal immunopathology and mortality, and inhibiting IRE1 reduces inflammation and improves survival.

bioRxiv · Nov 17, 2022Immunology

In vitro and in vivo activity of Gepotidacin against drug-resistant mycobacterial infections

M. N. Ahmad, T. Garg, S. Singh, R. Shukla, R. VK, P. Kaur, S. Chopra, A. Dasgupta

This study evaluates Gepotidacin's activity against drug-resistant mycobacteria, showing potent in vitro and in vivo efficacy, resistance bypass, and synergistic potential.

bioRxiv · Aug 19, 2022Microbiology

CUB domain containing protein 1 (CDPC1) is a target for radioligand therapy in castration resistant prostate cancer

N. Zhao, k. Trepka, Y.-h. Wang, S. Chopra, N. Hooshdaran, H. Kim, J. Yang, J. Zhuo, S. Lim, K. K. Leung, E. Egusa, L. K. Zhang, A. Foye, J. Chou, F. Y. Feng, , R. Aggarwal

This paper evaluates CDCP1 as a target for radioligand therapy in mCRPC, showing its expression in most biopsies and demonstrating antitumor effects with 177Lu-4A06.

bioRxiv · Jun 17, 2021 · PreprintCancer Biology